Details of the Drug Reposition

General Information of This Drug (ID: DM2NLS9)

Drug Name
Ciprofloxacin XR   DM2NLS9
Synonyms
ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
15 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Prostatitis DISL8OGN N.A. Approved [1]
Staphylococcus aureus infection DISK6PTH N.A. Approved [2]
Malignant otitis externa caused by Pseudomonas aeruginosa DIS5C8KP N.A. Approved [2]
Chancroid DISMVLOF N.A. Approved [2]
Acute maxillary sinusitis DISEUB5R N.A. Approved [2]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [2]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [3]
Inflammation DISJUQ5T 1A00-CA43.1 Approved [2]
Bacillary dysentery DISFZHKN 1A02 Approved [2]
Gram-positive bacterial infection DISZ44JH 1B74-1G40 Approved [4]
Anthrax DISFPT78 1B97 Approved [2]
Crohn disease DIS2C5Q8 DD70 Approved [2]
Cystitis DIS2D4B9 GC00 Approved [2]
Traveler's diarrhea DIS4R0UE ME05.1 Approved [2]
Fever DISJGEAQ MG26 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Indications(s)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cystic fibrosis DIS2OK1Q CA25 Phase 2 [5]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Biliary cancer DISBZP12 2E92.7 Phase 1 [6]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peritonsillar abscess DISZZXTZ N.A. Withdrawn [7]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Escherichia coli infection DISPP65M 1A03 Discontinued in Phase 3 [8]
------------------------------------------------------------------------------------
5 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rhinoscleroma DISNSWVK N.A. Discontinued in Phase 2 [9]
Bacterial conjunctivitis DIST79FU N.A. Discontinued in Phase 2 [10]
Otitis externa DISYCORK AA00-AA13 Discontinued in Phase 2 [11]
Bacterial pneumonia DISPW7PH CA40.0 Discontinued in Phase 2 [12]
Urolithiasis DISNFTKT GB7Z Discontinued in Phase 2 [13]
------------------------------------------------------------------------------------
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial urinary tract infection DISNNJTF N.A. Discontinued in Phase 1 [14]
Typhoid fever DISP3NHR 1A07 Discontinued in Phase 1 [15]
------------------------------------------------------------------------------------

References

1 Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int. 2007 Jul;100(1):51-7.
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
5 Inhaled Ciprofloxacin for the Management of Infections in Non-Cystic Fibrosis Bronchiectasis (BE) Patients
6 Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9.
7 Bevacizumab With or Without Surgery for Adult Glioblastomas
8 Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease
9 A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
10 P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
11 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
12 Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
13 AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
14 Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
15 Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma